Close
0
Inquiry Basket

There is no product in the shopping cart, buy it!

Contact Us Follow us on
Hot Products
Monosaccharide Products
Oligosaccharide Products
Polysaccharide Products
Carbohydrate-based Surfactant Products
Blood Group Antigen Products
Glycoprotein Products
Glycopeptide Products
Nucleotide Sugar Products
Glycoprotein Assay Kits
Comprehensive Glycoprotein Reagents
Glycoengineered Cell Products
Glycoengineering Viral Particle Products
Glycolipid Products

Hyaluronidase (HYAL1) Development Service

Introduction to Hyaluronidase-1 (HYAL1)

HYAL1, also known as hyaluronoglucosaminidase 1, is an acidic Glycosyl Functional Enzyme encoded by the gene located on chromosome 3p21.3. This Glycocalyx-Degrading Enzyme plays a pivotal role in degrading hyaluronic acid (HA) in the extracellular matrix by cleaving glycosidic bonds, producing low-molecular-weight HA fragments. HYAL1 is implicated in various physiological and pathological processes, including tumor progression, chronic inflammation, and connective tissue disorders. Its expression exhibits a dual role in cancer, promoting malignancy in certain contexts while suppressing metastasis in others, depending on the tumor microenvironment and signaling pathways involved.

Fig. 1. Localization of HYAL1-6 genes and secreted HYAL-mediated HA cleavage. (OA Literature) Fig.1 Schematic illustration depicting the chromosomal locations of hyaluronidases (HYALs) 1-6 and a secreted HYAL enzyme cleaving HA.1

Service Overview

Are you currently facing high costs in protein purification, inconsistent enzyme activity, or the structural complexity of targeting the tumor microenvironment? Creative Biolabs provides a comprehensive suite of solutions for HYAL1-related research, ranging from enzyme production for drug delivery applications to the identification of novel inhibitors for oncology. We address the technical bottleneck of the acidic-only activity profile of HYAL1, ensuring your leads are optimized for the low-pH environments of lysosomes and solid tumors.

HYAL1 Development Workflow

1
Gene Identification & Cloning Optimization
Development begins with gene mining from human genomic databases and optimizing cloning strategies for high-yield expression. Specialized vectors are designed to ensure proper folding and secretion, particularly for mammalian systems like CHO or HEK293 cells, which mimic native pH conditions.
2
Recombinant Protein Production & Purification
Using codon-optimized HYAL1 constructs, large-scale production is achieved via transient transfection or stable cell line development. Purification involves affinity chromatography and ion-exchange steps to remove host cell proteins.
3
Functional Characterization & Stability Testing
Stability studies assess thermal and pH tolerance, with formulations optimized for long-term storage.
4
Custom Formulation & Regulatory Support
Tailored solutions include HYAL1 conjugation to nanoparticles for targeted delivery or co-formulation with HA inhibitors to modulate activity.

Fig. 2. HYAL1 development workflow. (Creative Biolabs AI) Fig.2 Schematic illustration of HYAL1 development.

Service Highlights

High-Purity Recombinant HYAL1 Production

High-Purity Recombinant HYAL1 Production
Our service specializes in the scalable production of human recombinant HYAL1 using advanced mammalian or insect cell expression systems. Through rigorous purification protocols, we ensure >95% purity and consistent bioactivity, validated via SDS-PAGE, ELISA, and enzymatic assays.
Customizable Formulation & Functionalization

Customizable Formulation & Functionalization
We tailor HYAL1 variants to meet specific research or clinical needs, including peptide-tagged modifications for enhanced stability or detection. Our team collaborates closely with clients to optimize enzyme concentration, pH tolerance, and thermal stability, ensuring compatibility with diverse delivery systems.
End-to-End Analytical Support

End-to-End Analytical Support
From protein characterization to functional validation, we provide comprehensive analytical services. Our activity assays enable precise quantification of HYAL1 in complex matrices, while in vitro models assess biocompatibility and efficacy.
Rapid Turnaround & Cost Efficiency

Rapid Turnaround & Cost Efficiency
Leveraging high-throughput expression platforms, we deliver HYAL1 prototypes within 4-6 weeks, significantly reducing development timelines. Our modular pricing model accommodates projects of all scales.

Applications

  • Pharmaceutical Applications

HYAL1 enhances subcutaneous/intramuscular drug absorption by breaking down hyaluronic acid (HA) in tissues, lowering viscosity and facilitating faster diffusion. Studies show it improves antibiotic bioavailability, reducing treatment time.

  • Medical Aesthetics

When HA-based fillers are misplaced or overused, HYAL1 rapidly dissolves them, resolving lumps, asymmetry, or vascular blockages. It's the go-to solution for emergency filler reversal, preventing tissue damage within hours.

  • Metabolic Regulation

HYAL1 suppresses liver glucose production by degrading circulating HA, inhibiting mitochondrial ATP synthesis and key enzymes. Animal trials show a drop in fasting blood sugar, offering a new diabetes therapy path.

  • Oncology

HYAL1 breaks down HA-rich barriers in tumors, improving chemotherapy delivery and boosting T-cell infiltration. Early trials show it strengthens immunotherapy responses, making it a promising combo treatment.

  • Ophthalmology

During vitrectomies, HYAL1 liquefies the vitreous humor, easing blood/debris removal after injuries or retinal detachment. Its precision minimizes eye damage, improving recovery and reducing complications like glaucoma.

Collaborating to Ensure Continuity in Uncertain Times

Customer Reviews

Highly Professional
"The structure-guided engineering services offered by the HYAL1 team were truly enlightening. They not only provided us with deep insights but also facilitated a comprehensive understanding of the EGF-like domain's pivotal role in protein-protein interactions. This has been instrumental in advancing our research endeavors."- 4 weeks ago, Dr. Marcus T***n.

Cost-Effective
"By leveraging the whole-cell biocatalyst platform for HYAL1, we witnessed a remarkable reduction in our R&D overhead. This innovative approach not only streamlined our processes but also significantly cut down on costs, making it a highly cost-effective solution for our research needs."- 2 weeks ago, Dr. Sarah L***y.

FAQs

Q: Can your platform distinguish between HYAL1 and HYAL2 activity?

A: Yes. Because HYAL1 and HYAL2 have different substrate specificities and expression patterns, our assays are designed to specifically target the endoglycosidic breakdown signature unique to HYAL1, preventing cross-interference.

Q: Do I need to provide purified human enzymes for the project?

A: No. We utilize the genetic sequence to display the human enzyme on our bacterial platform, saving you the time and expense of sourcing and stabilizing purified proteins.

Q: How do you ensure the enzyme is correctly folded on the cell surface?

A: We perform validation zymography and substrate-specific activity tests to ensure the displayed HYAL1 mimics the native 2.0 Å crystal structure's catalytic cleft orientation and functionality.

Q: Are your inhibitors suitable for tumor microenvironment research?

A: Yes, our screening is specifically optimized for acidic pH conditions, which are characteristic of solid tumor environments, ensuring your leads are functional where it matters most in a clinical setting.

Extended Services

Custom Glycan Synthesis Services

Our custom glycan synthesis services offer tailored solutions to precisely construct complex glycans according to your specific research or industrial requirements, ensuring high purity and accuracy.

Sugar based Intermediate Synthesis Service

Our sugar based intermediate synthesis service specializes in the synthesis of key sugar-derived intermediates, providing high-quality building blocks for your pharmaceutical or chemical synthesis processes.

How to Contact Us

Creative Biolabs provides the scientific depth and technological agility needed to master HYAL1-targeted therapies. From structural mapping to high-throughput screening, we are your partners in biological excellence. Ready to accelerate your project? Our team of specialists is standing by to provide a detailed technical assessment of your needs. Contact us now!

Reference

  1. Kaul, Aditya, et al. "Hyaluronidases in human diseases." International Journal of Molecular Sciences 22.6 (2021): 3204. Distributed under an Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms22063204
For Research Use Only.

Related Services

Online Inquiry
Copyright © Creative Biolabs. All Rights Reserved.